PSYCHEDELICS FOR TREATMENT OF PAIN
A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect.
1 . A method of treating pain, including the steps of:
administering an effective amount of a psychedelic to an individual; and
treating pain in the individual.
2 . The method of claim 1 , wherein the pain is a type chosen from the group consisting of acute, chronic, nociceptive, neuropathic, inflammatory, and functional.
3 . The method of claim 1 , wherein the pain is caused by a physical state in the individual's body.
4 . The method of claim 1 , wherein the pain is caused by an emotional state in the individual's body.
5 . The method of claim 1 , wherein the psychedelic is chosen from the group consisting of lysergic acid diethylamide (LSD), psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamine (DOB), desoxyscalines, salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, and homologues thereof.
6 . The method of claim 1 , wherein said treating step is further defined as providing a psychological effect and a direct neural effect to the individual.
7 . The method of claim 1 , wherein said administering step is further defined as administering the psychedelic in a form chosen from the group consisting of transdermal patches, modified-release oral dosage forms, extended-release injection, implanted titration device, intranasal delivery forms, and sublingual delivery forms.
8 . The method of claim 1 , further including the step of treating inflammation in the individual.
9 . The method of claim 8 , further including the step of changing the levels of biomarkers of inflammation in the individual.
10 . The method of claim 9 , wherein the biomarkers are chosen from the group consisting of IL-1, IL-6, TNF-alpha, IFN-gamma, IL-4, IL-10, IL-12, IL-13, MCP-1, GM-CSF, YKL-40, CRP, or TGF-beta.
11 . The method of claim 1 , further including the step of administering an anti-inflammatory/anti-pain agent chosen from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDS), steroids, immune selective anti-inflammatory derivatives (ImSAIDs), narcotics, analgesics, biologic agents, and combinations thereof.
12 . The method of claim 11 , wherein said step of administering an anti-inflammatory/anti-pain is performed before, during, or after said administering the psychedelic step.
13 . The method of claim 11 , wherein the psychedelic and anti-inflammatory/anti-pain agent are in the same single dosage form or different dosage forms.
14 . A method of treating a pain syndrome, including the steps of:
administering an effective amount of a psychedelic to an individual; and
providing a central effect, an effect on depression and anxiety, and an anti-inflammatory effect.
15 . The method of claim 14 , wherein the psychedelic is chosen from the group consisting of lysergic acid diethylamide (LSD), psilocybin, psilocin, mescaline, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamine (DOB), desoxyscalines, salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, and homologues thereof.
16 . The method of claim 14 , further including the step of administering an anti-inflammatory/anti-pain agent chosen from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDS), steroids, immune selective anti-inflammatory derivatives (ImSAIDs), narcotics, analgesics, biologic agents, and combinations thereof.